Oragenics Inc (OGEN): who owns it and who trades it
As of Nov 16, 2026, OGEN insiders reported 1 open-market sale worth $197 and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Fred Telling (Director), with $197. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Oragenics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, OGEN insiders reported $0 of open-market purchases and $197 of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | Fred Telling | Director | Sale | 210 | $0.94 | $197 | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Fred Telling | Director | – | $197 | Dec 12, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
OGEN short interest
High short interest. 18.5% of OGEN shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 27%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 835,778 OGEN shares were sold short, 18.5% of the shares outstanding, down 0.1% from the report before. At the average daily volume of 20,858 shares, buying them all back would take about 40.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 835,778 | 18.52% | -0% | 20,858 | 40.1 |
| Oct 15, 2026 | 836,995 | 18.55% | -1% | 22,798 | 36.7 |
| Sep 30, 2026 | 841,634 | 18.65% | +4% | 33,814 | 24.9 |
| Sep 15, 2026 | 806,542 | 17.88% | +1% | 21,810 | 37.0 |
| Aug 31, 2026 | 794,915 | 17.62% | +1% | 52,605 | 15.1 |
| Aug 14, 2026 | 788,923 | 17.49% | +1% | 20,177 | 39.1 |
| Jul 31, 2026 | 781,094 | 18.01% | -0% | 24,984 | 31.3 |
| Jul 15, 2026 | 783,091 | 18.06% | +1% | 27,313 | 28.7 |
| Jun 30, 2026 | 775,021 | 17.87% | +3% | 46,036 | 16.8 |
| Jun 15, 2026 | 752,810 | 17.36% | +6% | 57,790 | 13.0 |
| May 29, 2026 | 708,926 | 16.35% | +8% | 42,399 | 16.7 |
| May 15, 2026 | 656,580 | 15.14% | -4% | 55,742 | 11.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Oragenics company events
Oragenics filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, listing). The latest was on Sep 16, 2026.
- Sep 16, 2026AnnouncementThe Company issued a press release announcing that its Chief Medical Officer is scheduled to present in the Successful Case Studies session at the IPAC-RS 2026 Nasal Innovation Forum on Thursday, September 17, 2026. Filing
- Aug 28, 2026ListingOragenics, Inc. received notification from the NYSE American LLC that the Company is no longer in compliance with NYSE American’s continued listing standards. Filing
- Jul 6, 2026LeadershipCompensatory Arrangements of Certain Officers. Filing
- May 19, 2026AnnouncementIssued a press release providing an update to its Shareholders. Filing
- May 7, 2026AnnouncementOragenics, Inc. issued a press release announcing that it has signed a Letter of Intent with Sigyn Therapeutics, Inc. to license CardioDialysis™, an extracorporeal blood purification technology designed to enable broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream. Filing
- Apr 13, 2026AnnouncementOragenics, Inc. issued a press release announcing that the first patient has been dosed in the Company’s ongoing Phase IIa clinical trial in Australia, evaluating ONP-002, the Company’s lead candidate for the treatment of concussion and mild traumatic brain injury (mTBI). Filing
- Mar 31, 2026VoteSet dates for shareholder nominations. Filing
- Mar 11, 2026AnnouncementOragenics, Inc. issued a press release announcing that it had received final Human Research Ethics Committee (HREC) approval in Australia to commence the Company’s Phase IIa clinical trial evaluating the Company’s lead drug candidate, ONP-002, for the treatment of concussion and mild traumatic… Filing
- Jan 22, 2026AgreementAs previously disclosed, on October 11, 2024, Oragenics, Inc. entered into an At-the-Market Sales Agreement with Dawson James Securities Inc. pursuant to which the Company may issue and sell, from time to time, shares of its common stock, depending on market demand, with the Sales Agent acting as… Filing
- Jan 20, 2026AnnouncementShared information with investors. Filing
- Dec 15, 2025LeadershipCompensatory Arrangements of Certain Officers. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Oragenics financials
Famous investors that hold OGEN
1 of the 50 well-known investors we track reported holding OGEN in their latest 13F filing. The largest position is Ken Griffin's, worth $6.6K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 13,514 | $6.6K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Oragenics Inc (OGEN) stock
Are OGEN insiders buying or selling?
In the last 12 months, OGEN insiders reported no open-market purchases and 1 sale worth $197. The latest trade was on Dec 12, 2025. See every trade.
What is the short interest in OGEN?
As of Oct 30, 2026, 835,778 OGEN shares were sold short, 18.5% of the shares outstanding, down 0.1% from the report before. At the average daily volume of 20,858 shares, buying them all back would take about 40.1 trading days (days to cover). See the history.
Which famous investors hold OGEN?
1 of the 50 well-known investors we track reported OGEN in their latest 13F filing, including Ken Griffin. The largest position is worth $6.6K. See all holders.
Executive pay
Oragenics's chief executive was paid a total of $609K for the year ended Dec 31, 2025, down 18% from $745K the year before. In the last 12 months, Oragenics's executives and directors bought no stock on the open market and sold $197.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.